Spectral AI (MDAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for May 29, 2026, with both in-person and virtual attendance options.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online and by request.
Voting matters and shareholder proposals
Election of five directors to serve until the next annual meeting or until successors are elected and qualified.
Ratification of Forvis Mazars, LLP as independent registered public accounting firm for fiscal year 2026.
Authorization to reserve and issue shares of common stock for sale to Hudson Bay Master Fund Ltd. under a Securities Purchase Agreement dated October 24, 2025.
Provision to transact any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all three main proposals.
Director nominees include Dr. J. Michael DiMaio, Richard Cotton, Martin Mellish, Deepak Sadagopan, and Marion Snyder.
Latest events from Spectral AI
- FDA clearance enables 2026 commercial launch; net loss narrows, cash at $14M, revenue still government-based.MDAI
Q2 2026 - Q1 2026 revenue fell to $4.0M, net loss was $3.4M, and BARDA funding advanced DeepView.MDAI
Q1 2026 - Shareholders will vote on director elections, auditor ratification, and a significant share issuance.MDAI
Proxy filing - Shareholders will vote on director elections, auditor ratification, and a significant share issuance.MDAI
Proxy filing - 2025 net loss narrowed, cash rose to $15.4M, and 2026 revenue is forecast at $18.5M.MDAI
Q4 2025 - Q3 revenue up 138% to $8.2M, margins improved, and FDA submission and spin-off plans advance.MDAI
Q3 2024 - AI-driven wound care system nears FDA submission, with UK pilots and strong funding support.MDAI
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Q2 revenue up 76% year-over-year; UK commercialization and FDA submission on track.MDAI
Q2 2024 - Record R&D revenue and clinical validation position DeepView for 2025 FDA submission.MDAI
Q4 2024